A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Melanoma · Clear-Cell Renal-Cell Carcinoma (ccRCC) · Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 240 (planned)
- Started
- Sep 23, 2024
- Main results expected
- Feb 3, 2030
- Fully finished
- Feb 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose-Limiting Toxicities (DLTs)
Measured over: Up to Day 29
Incidence of Treatment-Emergent Adverse Event (TEAEs)
Measured over: Approximately 6 Years
Incidence of Serious Adverse Events (SAEs)
Measured over: Approximately 6 Years
Incidence of TEAEs leading to treatment discontinuation
Measured over: Approximately 6 Years
Incidence of TEAEs leading to death
Measured over: Approximately 6 Years
Number of participants with Grade 3 laboratory abnormalities
Measured over: Approximately 6 Years
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria by investigator assessment
Measured over: Approximately 6 Years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06413680 · record last updated 2026-04-28 · checked 2026-11-09 15:47 UTC